Sector News

Can Medivation's CEO get a bidding war started?

May 10, 2016
Life sciences

It may soon get crowded at the bargaining table for a Medivation buyout. This morning Bloomberg reported that Amgen is now actively pondering a bid for the biotech. The news follows Sanofi’s $9.3 billion bid as well as Pfizer’s reported interest in making its own offer.

A bidding war would suit Medivation CEO David Hung perfectly. The biotech spurned Sanofi’s $52.50 per share offer and will now get to consider its defensive strategy now that Sanofi has threatened to go hostile and go after its board unless they get serious about negotiating a deal.

There’s no certainty that either Pfizer or Amgen will make an offer for a company that would deliver the prostate cancer drug Xtandi as well as an experimental PARP inhibitor. But every new report of added interest can only add to the pressure on Sanofi to increase its bid. And AstraZeneca as well as Novartis have also been rumored to be among the potential suitors.

Analysts have speculated that Medivation’s price could go all the way to $70 a share, which would provide a big premium for investors. For Hung, who captured the attention of the industry with high-dollar collaborations in cancer as well as Alzheimer’s, extracting the biggest price for the company’s stock could be his last big play at Medivation. A few well placed news stories can only help him on that quest.

By John Carroll

Source: Fierce Biotech

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach